XRP price could hit $21 with Fortune 500 investments

A new analysis explores the potential impact on XRP's price if the top 10 Fortune 500 companies allocate 5% of their revenues to the cryptocurrency. This hypothetical scenario assumes significant inflows from major U.S. firms amid growing corporate interest in XRP treasuries. The projection suggests a substantial market cap boost under conservative estimates.

As U.S. regulators clarify crypto laws, several companies have begun incorporating XRP into their treasuries. VivoPower committed millions in May 2025, followed by Webus International's $300 million plan in June. Trident Digital Tech Holdings announced a $500 million purchase, Wellgistics Health added $50 million, and Evernorth revealed a $1 billion commitment last month.

The Fortune 500 ranks America's largest companies by revenue, with the 2024 list led by Walmart at $648.1 billion, Amazon at $574.8 billion, and Apple at $383.3 billion. UnitedHealth Group reported $371.6 billion, Berkshire Hathaway $364.5 billion, CVS Health $357.8 billion, ExxonMobil $344.6 billion, Alphabet $307.4 billion, McKesson $276.7 billion, and Cencora $262.2 billion.

In this analysis, each of these top 10 firms invests 5% of its revenue in XRP, totaling about $194.55 billion. Walmart would contribute $32.405 billion, Amazon $28.74 billion, Apple $19.165 billion, UnitedHealth Group $18.58 billion, and Berkshire Hathaway $18.225 billion, with the rest making up the balance.

Such inflows would not directly mirror market cap increases due to crypto's multiplier effect. Past XRP cases have shown multipliers up to 272x, but applying a conservative 10x here, the $194.55 billion could elevate the market cap by $1.945 trillion. From XRP's current $139 billion valuation, this would reach roughly $2.084 trillion.

With a total supply of about 99.9 billion tokens, the price per XRP would then stand at around $21. Note that companies typically invest from profits, not full revenue, after covering costs like operations and taxes. This scenario remains speculative and does not constitute financial advice.

This website uses cookies

We use cookies for analytics to improve our site. Read our privacy policy for more information.
Decline